CFO at Stoke Therapeutics (NASDAQ: STOK) receives new equity grants

Rhea-AI Filing Summary

Leggett Thomas reported acquisition or exercise transactions in this Form 4 filing.

Stoke Therapeutics, Inc. reported that its Chief Financial Officer, Thomas Leggett, received new equity awards. He was granted an option to buy 60,000 shares of common stock at no cost on the grant date, which will vest in monthly installments over four years starting March 15, 2026, contingent on continued service. He also received 40,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning February 15, 2027, also conditioned on his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Leggett Thomas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	60,000	$0.00	--
Grant/Award	Restricted Stock Units	40,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 60,000 shares (Direct); Restricted Stock Units — 40,000 shares (Direct)

Footnotes (1)

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leggett Thomas

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$31.09	02/17/2026		A		60,000		(1)	02/16/2036	Common Stock	60,000	$0	60,000	D
Restricted Stock Units	(2)	02/17/2026		A		40,000		(3)	02/15/2030	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

3. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Stoke Therapeutics (STOK) report for its CFO?

Stoke Therapeutics reported that its Chief Financial Officer, Thomas Leggett, received equity awards of stock options and restricted stock units. The grants consist of 60,000 options and 40,000 RSUs, both subject to time-based vesting and his continued service with the company.

How many stock options did the Stoke Therapeutics (STOK) CFO receive?

The Chief Financial Officer received an option to buy 60,000 shares of Stoke Therapeutics common stock. The option vests as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary, assuming continued service with the company.

What are the vesting terms of the Stoke Therapeutics (STOK) CFO’s stock options?

The CFO’s 60,000-share stock option vests monthly over four years. Vesting begins with 1/48 of the award on March 15, 2026, then 1/48 on each monthly anniversary, provided he remains in continuous service to Stoke Therapeutics through each vesting date.

What restricted stock unit (RSU) grant did the Stoke Therapeutics (STOK) CFO receive?

The Chief Financial Officer received 40,000 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in four equal annual installments, beginning on February 15, 2027, subject to his continued service with Stoke Therapeutics.

When do the Stoke Therapeutics (STOK) CFO’s RSUs start vesting?

The 40,000 restricted stock units granted to the CFO start vesting on February 15, 2027. One quarter of the award vests annually on that date, for four years, as long as he continues to serve the company through each vesting date.

Does each RSU granted to the Stoke Therapeutics (STOK) CFO equal one share?

Each restricted stock unit granted to the CFO represents a contingent right to receive one share of Stoke Therapeutics common stock. Shares are delivered upon settlement of the RSUs, subject to vesting conditions being satisfied and his continued service with the company.